Sorted By:

Relevance


Foreign government pricing setting by any name harms innovation and access to medicines

PhRMA  |  Blog Post

Ad-hoc price cuts and clawbacks require manufacturers to pay discounts and even return revenue earned to cover short-term government deficits.
http://catalyst.phrma.org/foreign-gov-pricing-setting-by-any-name-harms-innovation-and-access-to-medicines

4 Things to know about the QuintilesIMS Medicines Use and Spending in the U.S. report

PhRMA  |  Blog Post

But, in order to have productive conversations, we need to be using the same set of facts.
http://catalyst.phrma.org/4-things-to-know-about-the-quintilesims-medicines-use-and-spending-in-the-us-report

Medicines in Development for Children 2012 Report

PhRMA  |  Report

Biopharmaceutical research companies are working to continue this progress and to meet new health challenges specific to children.
https://www.phrma.org/report/medicines-in-development-for-children-report

Burden on Patients: Questions on Access to Cancer Medicines in Health Exchange Plans

PhRMA  |  Blog Post

We have expressed these concerns to HHS, state insurance commissioners, and others, and we encourage all parties to work together to ensure that coverage sold in the exchanges is more than adequate to meet the needs of people with cancer.
http://catalyst.phrma.org/burden-on-patients-questions-on-access-to-cancer-medicines-in-health-exchange-plans

Access to Multiple Sclerosis Medicines in Exchange Plans

Access Better Coverage  |  From Our Network

For an analysis of health insurance exchange coverage in 2015, view this fact sheet.
http://www.accessbettercoverage.org/factsheets/access-to-multiple-sclerosis-medicines-in-exchange-plans

Medicare Monday: A closer look at Part B spending

PhRMA  |  Blog Post

In fact, Part B drug spending has historically been a stable share of overall Part B spending and is expected to remain so in the future.
http://catalyst.phrma.org/medicare-monday-a-closer-look-at-part-b-spending

Deputy Vice President – Policy and Research

PhRMA  |  PhRMA Career

Accordingly, the successful candidate should be adaptable, able to reprioritize and shift gears quickly.
https://www.phrma.org

Fighting multiple sclerosis: New Together ad illuminates the journey of patient & scientist

PhRMA  |  Blog Post

Check out the other exciting GOBOLDLY™ advertisements launched so far this year.
http://catalyst.phrma.org/fighting-multiple-sclerosis-new-together-ad-illuminates-the-journey-of-patient-scientist

Prescription Medicines: Costs in Context

PhRMA  |  From PhRMA

And every additional dollar spent on medicines for adherent patients with congestive heart failure, high blood pressure, diabetes and high cholesterol generated $3 to $10 in savings on emergency room visits and inpatient hospitalizations.
https://www.phrma.org/advocacy/cost-and-value

Sharing Negotiated Discounts Could Save Patients More than $800 Annually and Would Increase Premiums About 1 Percent

PhRMA  |  Press Release

She would save approximately $359 annually if negotiated discounts were shared.
https://www.phrma.org/press-release/sharing-negotiated-discounts-could-save-patients-more-than-800-annually-and-would-increase-premiums-about-1-percent

Burden on Patients: 5 Questions on Access to Mental Health Medicines in Health Exchange Plans

PhRMA  |  Blog Post

We’ve seen a significant amount of aggressive utilization management, particularly for classes like anti-psychotics.
http://catalyst.phrma.org/burden-on-patients-5-questions-on-access-to-mental-health-medicines-in-health-exchange-plans

Pediatrics

PhRMA  |  From PhRMA

Learn more here.
https://www.phrma.org/pediatrics

What makes Valeant different than innovative biopharmaceutical companies?

PhRMA  |  Blog Post

According to the National Science Foundation, the sector is the single largest funder of business R&D in the U.S., representing about one in every five dollars spent on domestic R&D by U.S. businesses.
http://catalyst.phrma.org/what-makes-valeant-different-than-innovative-biopharmaceutical-companies

Week in Review: The Latest from PhRMA

PhRMA  |  Blog Post

TPP Should Protect Medical Innovation: The Wall Street Journal and The Washington Post recently editorialized that any deal on the Trans-Pacific Partnership (TPP) must protect the investment in research and development required to bring biologics to market, which is of particular value to America’s patients.
http://catalyst.phrma.org/week-in-review-the-latest-from-phrma-august-14-2015

Together - Alzheimer's Disease

PhRMA  |  Video

When Brian and Samantha look in the mirror every day they both see the same thing: Hope.
https://www.phrma.org/video/together-alzheimer-s-disease

Policy conditions make or break leaders in biopharmaceutical innovation: Preliminary results from the 2017 BCI Survey

PhRMA  |  Blog Post

In fact, each country in the BCI holds the keys to success for improving or maintaining an environment that attracts biopharmaceutical investment today.
http://catalyst.phrma.org/policy-conditions-make-or-break-leaders-in-biopharmaceutical-innovation-preliminary-results-from-the-2017-bci-survey

Innovations in Mental Health Care

PhRMA  |  Video

“We are moving from developing medicines for patients,” she said, “to developing medicines with patients.”
https://www.phrma.org/video/innovations-in-mental-health-care

World AIDS Day 2016: A decade of scientific innovation

PhRMA  |  Blog Post

In fact, the annual number of new diagnoses declined by 19 percent from 2005 to 2014 in the U.S.
http://catalyst.phrma.org/world-aids-day-2016-a-decade-of-scientific-innovation

Burden on Patients: 5 Questions on Access to HIV/AIDS Medicines in Health Exchange Plans

PhRMA  |  Blog Post

In fact, some plans are putting all of the HIV drugs on the highest tier.
http://catalyst.phrma.org/burden-on-patients-5-questions-on-access-to-hiv/aids-medicines-in-health-exchange-plans

Government-imposed price controls threaten innovation and access

PhRMA  |  Blog Post

As a result, patients get the short end of the stick with severely reduced access to innovative medicines.
http://catalyst.phrma.org/government-imposed-price-controls-threaten-innovation-and-access

A new era in cancer

PhRMA  |  Blog Post

The last few years have seen unparalleled progress in cancer care, with breakthrough research driving major advances in diagnosis and treatment.
http://catalyst.phrma.org/a-new-era-in-cancer

This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system

PhRMA  |  Blog Post

Cells is a rarely seen, front row seat to the destruction of a cancer cell by the body’s own immune system stimulated by new advancements in immuno-oncology.
http://catalyst.phrma.org/this-is-not-a-video-game-new-tv-ad-showcases-the-destruction-of-a-cancer-cell-by-immune-system

Burden on Patients: 5 Questions on access to multiple sclerosis medicines in health exchange plans

PhRMA  |  Blog Post

We also see limits on other medically necessary benefits for people with MS, like physical, occupational and speech/language therapies.
http://catalyst.phrma.org/burden-on-patients-5-questions-on-access-to-multiple-sclerosis-medicines-in-health-exchange-plans

New 2010 R&D Numbers Demonstrate Our Commitment

PhRMA  |  Blog Post

They don't enjoy short-term rewards, but rather persevere each day, each month and each year in the hopes that down the line, they'll see the reward.
http://catalyst.phrma.org/new-2010-rd-numbers-demonstrate-our-commitment

Economic Impact

PhRMA  |  From PhRMA

Explore all fact sheets at the Industry Economic Impact page for the entire United States, the 50 states and the District of Columbia.
https://www.phrma.org/media/economic-impact

You have reviewed the first 225 results out of 1198. Each page contains 25 results. You're on page 9.

prev 7 8 9 10 11 12 next